Life trial losartan pdf

Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study life. We found large variability in individual aortic root dilatation rates in the losartan group and losartan treatment did not normalize the dilatation rate to that of the healthy population aortic root dilatation rate of 0. Comparison of the efficacy of candesartan and losartan. May 21, 2004 the life trial was conducted on an international basis in scandinavia, the usa and the uk. It is approved in numerous countries for the treatment of hypertension and has been approved in the uk, the us and several european countries for stroke risk reduction in patients with hypertension and left ventricular hypertrophy lvh. The losartan intervention for endpoint reduction in hypertension life trial was an actively controlled clinical trial of 4. Effects of losartan on renal and cardiovascular outcomes. Oct 01, 2019 losartan potassium was effective in reducing blood pressure regardless of race, although the effect was somewhat less in black patients usually a lowrenin population. The losartan intervention for endpoint reduction in hypertension study life is the only completed hypertension trial of an arb to assess cardiovascular outcomes. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study life. It may be used alone or in addition to other blood pressure medication. This conclusion is based on an analysis of the patients with diabetes enrolled in the losartan intervention for endpoint reduction in hypertension life study. Effects of losartan on cardiovascular morbidity and mortality.

Oct 25, 2003 lars lindholm and colleagues aug 23, p 6191 suggest that losartan is better than atenolol in reducing sudden cardiac death in diabetic hypertensives with leftventricular hypertrophy. Losartan intervention for endpoint reduction in hypertension life study 09543 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Clinical trials for losartan the european union clinical trials register allows you to search for protocol and results information on. Losartan reduces aortic dilatation rate in adults with. May 31, 2007 ultimately, hard end point trials are needed to provedisprove the merit of a drug class. Mar 23, 2002 the primary hypothesis of the life study was that selective angiotensinii type 1receptor antagonism with losartan would be more effective than. Losartan to reduce inflammation and fibrosis endpoints in hiv. Im in the telaprevir trial and i go to the study nurse almost every week to get the blood test and to get a quick physical well every time. Methods subjects the life trial16,17 enrolled hypertensive patients with ecg lvh by cornell voltageduration product18 andor sokolowlyon voltage criteria1 on a screening ecg in a prospective, doubleblind study large enough n 9193 to demonstrate that an appreciable reduction in mortality and morbid events is associated with use of losartan as. Losartan reduced cardiovascular morbidity and mortality more than. Sep 17, 2012 losartan cozaar is an angiotensin at1 receptor antagonist. In addition, in the life trial the lower rate of newonset diabetes difference of 25% with losartan confirms findings from prior studies. Losartan vs atenolol in htn and lvhgreat reduction in cardiovascular morbidity and death than. The benefit of losartan over atenolol was more pronounced in a separate trial of hypertensive diabetic patients with left ventricular hypertrophy nnt 122 patients per year.

We are uncomfortable with this conclusion because we and. To measure healthrelated qualityoflife hrqol in elderly symptomatic heart failure patients following treatment with an angiotensin ii receptor antagonist losartan vs. Dec 17, 2009 the life losartan intervention for endpoint reduction in hypertension trial 30 showed that with equal bp control, a losartanbased regimen was superior in reducing cv end points mainly stroke. Lars lindholm and colleagues aug 23, p 6191 suggest that losartan is better than atenolol in reducing sudden cardiac death in diabetic hypertensives with leftventricular hypertrophy. The losartan intervention for endpoint reduction life trial. Listing a study does not mean it has been evaluated by the u.

The losartan intervention for endpoint reduction in hypertension life study demonstrated that losartanbased therapy reduced cardiovascular end points significantly better than atenololbased therapy for a similar reduction in blood pressure bp in patients with hypertension and left ventricular hypertrophy lvh. Ultimately, hard end point trials are needed to provedisprove the merit of a drug class. The losartan intervention for endpoint reduction life in. Fifteen years of life losartan intervention for endpoint. Losartan, sold under the trade name cozaar among others, is a medication mainly used to treat high blood pressure. In patients with type ii diabetes and nephropathy, losartan at a dose of 50100 mg daily significantly reduced the risk of developing endstage renal disease compared to placebo. There are several more subgroup analyses yet to be published and also many official life trial substudies.

The effect of losartan versus atenolol on cardiovascular. Losartan, the first angiotensin receptor blocker, was shown to exert significant cardioprotective and renoprotective effects in the life losartan intervention for endpoint reduction in hypertension and renaal reduction of endpoints in niddm with the angiotensin ii antagonist losartan trials. Electrocardiographic strain pattern and prediction of. Losartan intervention for endpoint reduction in hypertension.

The costeffectiveness of losartan versus atenolol in the treatment of hypertension was analyzed by applying the results of the life study to the swiss healthcare system using a decision analysis. Listing a study does not mean it has been evaluated by. Cardiovascular morbidity and mortality in the losartan. The losartan intervention for endpoint reduction life in hypertension study is a doubleblind, prospective, parallel group study designed to compare the effects of losartan with those of the betablocker atenolol on the reduction of cardiovascular morbidity and mortality in approximately 8,300 hypertensive patients initial sitting diastolic. Is hydrochlorothiazide more effective on lvh in nonresponders. Neither losartan nor its metabolite accumulate in plasma upon repeated oncedaily dosing. Published in 2002, the cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension life trial was conducted to determine if administration of losartan compared to atenolol in hypertensive patients would confer further reduction in cardiovascular morbidity and mortality independent from effects on. Letter regarding article by devereux et al, regression of. The life trial showed that losartan produced better cardiovascular protection than atenolol, a similar blood pressure reduction, and was better tolerated. The losartan intervention for endpoint reduction life triala. The lifehiv trial is a critical step to advance this field, prior to conducting a clinical outcome trial, by testing the effects of losartan treatment in a translational clinical trial that will improve our understanding of nonaids disease pathogenesis. This fdaapproved indication is based on the findings of the life trial which compared losartan vs. In cohort substudies of the life trial, regression of lvh was associated with reduced risk for new. Published in 2002, the cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension life trial.

The life trial compared the effectiveness of losartan and atenolol on bp. The life trial was conducted on an international basis in scandinavia, the usa and the uk. Apr 16, 2020 in addition, in the life trial the lower rate of newonset diabetes difference of 25% with losartan confirms findings from prior studies with the ace inhibitors ramipril and captopril. The conclusion of devereux et al, the authors of the recently published study of the large losartan intervention for endpoint reduction in hypertension life trial, 1 was that losartan has direct cardiac benefits because brachial blood pressure lowering with losartan and atenolol was comparable. Question what is the association of total neoadjuvant treatment with folfirinox fluorouracil, leucovorin, oxaliplatin, and irinotecan, losartan, and chemoradiation therapy with marginnegative r0 resection rates in patients with locally advanced pancreatic adenocarcinoma findings in this singlearm phase 2 trial of 49 patients, the r0 resection rate. What is the best regimen for newly diagnosed hypertension. An overview of generic angiotensin receptor blockers. The losartan intervention for endpoint reduction in hypertension life study demonstrated that losartan based therapy reduced cardiovascular end points significantly better than atenololbased therapy for a similar reduction in blood pressure bp in patients with hypertension and left ventricular hypertrophy lvh. The terminal halflife of losartan is about 2 hours and of the metabolite is about 69 hours. Intervention for endpoint reduction in hypertension study life.

Well absorbed after oral administration but undergoes substantial firstpass metabolism. Effects of losartan on cardiovascular morbidity and mortality in. Two longterm trials have compared an arb to other types of drug therapy. Pdf cardiovascular morbidity and mortality in patients. Pediatric hypertension the antihypertensive effect of losartan was studied in one trial enrolling 177 hypertensive pediatric patients aged 6 to 16 years old. Our general goal is to evaluate the potential effectiveness of losartan 100mg daily for reducing inflammation and improving immune recovery, given the potential for these treatment effects to reduce risk for longterm nonaidsdefining complications among older hiv positive participants. Losartan intervention for endpoint reduction in hypertension trial. The life losartan intervention for endpoint reduction in hypertension trial 30 showed that with equal bp control, a losartanbased regimen was superior in reducing cv end points mainly stroke. Losartan reduces aortic dilatation rate in adults with marfan. Losartan to reduce inflammation and fibrosis endpoints in. Effects of highdose versus lowdose losartan on clinical outcomes in patients with heart failure heaal study. Cardiovascular morbidity and mortality in the losartan intervention. In this trial, losartan reduced the risk of stroke nonfatal and fatal by 25% compared to atenolol.

The findings from one such trial, the losartan intervention for endpoint reduction in hypertension life study, were recently published and offer important insights into the workings of this drug class. The losartan intervention for endpoint reduction life in hypertension study. The findings from one such trial, the losartan intervention for endpoint reduction in hypertension life study, were recently published and offer important insights into the workings of this drug. Original article from the new england journal of medicine effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Losartan more effective than atenolol in hypertension with. Although clinical evidence shows that calcium channel blockers and thiazidetype diuretics are preferred firstline treatments for most patients from both from an efficacy and cost point of view, an angiotensin ii receptor antagonist such as losartan is recommended as firstline treatment in younger patients under the age of 55 who cannot tolerate an ace inhibitor. Costeffectiveness of losartan versus atenolol in treating hypertensionan analysis of the life study from a swiss perspective. If further bp control is needed, increase the hctz dosage to 25 mg po once daily. In addition, in the life trial the lower rate of newonset diabetes difference of 25% with losartan confirms findings from prior studies with the ace inhibitors ramipril and captopril.

Up to six weeks may be required for the full effects to occur. Nov 05, 2018 losartan potassium pharmacokinetics absorption bioavailability. Effects of losartan or atenolol in hypertensive patients. The losartan intervention for end point reduction life was a landmark trial that, in addition to its main results supporting the superiority of a losartanbased over an atenololbased regimen, 1 produced an impressive number of ancillary studies related to left ventricular hypertrophy lvh and other manifestations of organ damage in patients with hypertension. Losartan, the first angiotensin receptor blocker, was shown to exert signi. Losartan fda prescribing information, side effects and uses. Life trial at the 51st annual scientific session of. Neither losartan nor its metabolite accumulate in plasma. Jun 15, 2018 in cohort substudies of the life trial, regression of lvh was associated with reduced risk for new. The reduction of endpoints in niddm with the angiotensin ii antagonist losartan renaal trial randomized 1,5 patients with noninsulindependent t2dm and nephropathy to losartan or placebo in addition to conventional antihypertensive therapy excluding ace inhibitors.

Fifteen years of life losartan intervention for endpoint reduction. Losartan reduced cardiovascular morbidity and mortality. Cozaar losartan potassium dose, indications, adverse. The losartan intervention for endpoint reduction trial is one of several endpoint trials that are now available with angiotensinreceptor blockers. Effects of losartan on cardiovascular morbidity and. The losartan intervention for endpoint reduction trial is one of several end. Ongoing inflammation contributes to excess cvd, cancer and disease in multiple organ systems. It is also used for diabetic kidney disease, heart failure, and left ventricular enlargement. Beyond blood pressure reduction in the treatment of arterial. Pdf costeffectiveness of losartan versus atenolol in. The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change over time.

The terminal half life of losartan is about 2 hours and of the metabolite is about 69 hours. Jun 16, 2016 the life trial cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study compared losartan with atenolol, a betablocker, to determine whether selective blocking of angiotensin ii improves left ventricular hypertrophy lvh beyond reducing blood pressure over 4 years. The losartan intervention for endpoint reduction life. Losartan potassium pharmacokinetics absorption bioavailability. The life trial in 2004 journal of human hypertension. Aug 05, 2003 effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease. Losartan to reduce inflammation and fibrosis endpoints in hiv trial lifehiv this study has been completed. Jun 20, 2006 losartan intervention for endpoint reduction in hypertension life study 09543 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Losartan is recommended for use alone or with hydrochlorothiazide, but it can also be. Openurl1crossref2pubmed3web of science4 this study by konstam and colleagues in some ways expands on the findings of the evaluation of. Compared with lowdose losartan, highdose losartan decreases. Openurl1crossref2pubmed3web of science4 this study by konstam and colleagues.

528 1017 943 192 182 1011 166 370 1287 560 279 1352 520 1594 695 225 1490 750 347 746 844 1110 89 672 207 630 1313 341 1559 184 849 1625 1484 183 1264 206 630 712 591 1138 185 77 1291 1007 669